Equities analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report earnings of ($0.63) per share for the current quarter, according to Zacks. Seven analysts have provided estimates for AMAG Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.85). AMAG Pharmaceuticals reported earnings per share of $1.57 during the same quarter last year, which indicates a negative year-over-year growth rate of 140.1%. The company is expected to announce its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that AMAG Pharmaceuticals will report full year earnings of ($3.44) per share for the current fiscal year, with EPS estimates ranging from ($3.56) to ($3.31). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.54) per share, with EPS estimates ranging from ($3.09) to ($0.47). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.54). The firm had revenue of $146.25 million for the quarter, compared to analysts’ expectations of $156.26 million. AMAG Pharmaceuticals had a negative net margin of 36.87% and a negative return on equity of 2.77%. The firm’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.40) earnings per share.

A number of analysts have recently issued reports on the stock. BidaskClub downgraded shares of AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, May 28th. ValuEngine downgraded shares of AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 21st. B. Riley raised shares of AMAG Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $23.00 to $30.00 in a report on Friday, June 15th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $18.00 price objective (up from $17.00) on shares of AMAG Pharmaceuticals in a report on Friday, August 3rd. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $22.00 price objective on shares of AMAG Pharmaceuticals in a report on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $22.87.

In other AMAG Pharmaceuticals news, CEO William K. Heiden sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the chief executive officer now directly owns 328,015 shares of the company’s stock, valued at $8,200,375. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.00% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Advisors Asset Management Inc. lifted its stake in AMAG Pharmaceuticals by 791.6% in the second quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 52,356 shares during the last quarter. Piedmont Investment Advisors LLC purchased a new position in shares of AMAG Pharmaceuticals in the second quarter valued at about $156,000. Meeder Asset Management Inc. increased its position in shares of AMAG Pharmaceuticals by 590.9% in the second quarter. Meeder Asset Management Inc. now owns 8,947 shares of the specialty pharmaceutical company’s stock valued at $174,000 after acquiring an additional 7,652 shares during the period. NumerixS Investment Technologies Inc increased its position in shares of AMAG Pharmaceuticals by 243.2% in the second quarter. NumerixS Investment Technologies Inc now owns 12,700 shares of the specialty pharmaceutical company’s stock valued at $257,000 after acquiring an additional 9,000 shares during the period. Finally, Sun Life Financial INC purchased a new position in shares of AMAG Pharmaceuticals in the second quarter valued at about $266,000.

AMAG opened at $20.90 on Tuesday. The firm has a market cap of $713.59 million, a PE ratio of -3.66 and a beta of 0.48. The company has a quick ratio of 1.95, a current ratio of 2.06 and a debt-to-equity ratio of 0.99. AMAG Pharmaceuticals has a one year low of $11.93 and a one year high of $26.10.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Further Reading: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.